Vimarsana
Biggest News Aggregation in the World

Page 17 - Refractory Multiple News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Refractory Multiple. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Refractory Multiple Today - Breaking & Trending Today

U.S. FDA Approves CARVYKTI™ (ciltacabtagene autoleucel), Janssen's First Cell Therapy, a BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma - Vimarsana News

U.S. FDA Approves CARVYKTI™ (ciltacabtagene autoleucel), Janssen's First Cell Therapy, a BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Published: March 1, 2022

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has approved CARVYKTI™...

Source: prnewswire.com
Related Topics:
United StatesObrian KenneyPeter LebowitzHemophagocytic LymphohistiocytosisCiltacabtagene AutoleucelSundar JagannathJessica MooreCaroline PavisMathai MammenJanssen Biotech IncTisch Cancer InstituteDrug AdministrationJanssen Research DevelopmentJanssen Pharmaceutical CompaniesJanssen Pharmaceutical Companies Of JohnsonNone Of Janssen Biotech IncAmerican Society Of HematologyExchange CommissionIcahn School Of Medicine At Mount SinaiCompanies Of JohnsonEuropean Medicines AgencyAmerican Cancer SocietyLegend Biotech United States IncLegend Biotech United StatesConfidence Interval
Johnson & Johnson Reports Q4 and Full-Year 2021 Results - Vimarsana News

Johnson & Johnson Reports Q4 and Full-Year 2021 Results

Published: January 25, 2022

/PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2021. "Our 2021 performance reflects continued strength...

Source: prnewswire.com
Related Topics:
South AfricaUnited StatesConsumer Health BusinessDigital Surgery SolutionsEuropean Commission ApprovesPaliperidone PalmitateMaintenance TreatmentMultiple Myeloma After FirstConditional Marketing AuthorisationFirst Treatment ApprovedAdvanced Nonsmall Cell Lung CancerMutations After FailureBooster Shot AuthorizedEmergency UseHealth Organization Strategic Advisory GroupInterim Recommendation Supports UseBooster ShotTwo New IndicationsHelp PreventTreat Blood ClotsSeeks ApprovalFixed Duration RegimenUntreated Chronic Lymphocytic LeukaemiaSubmits Biologics License ApplicationRefractory Multiple
Johnson & Johnson Reports Q4 and Full-Year 2021 Results - Vimarsana News

Johnson & Johnson Reports Q4 and Full-Year 2021 Results

Published: January 25, 2022

/PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2021. "Our 2021 performance reflects continued strength...

Source: prnewswire.com
Related Topics:
South AfricaUnited StatesConsumer Health BusinessDigital Surgery SolutionsEuropean Commission ApprovesPaliperidone PalmitateMaintenance TreatmentMultiple Myeloma After FirstConditional Marketing AuthorisationFirst Treatment ApprovedAdvanced Nonsmall Cell Lung CancerMutations After FailureBooster Shot AuthorizedEmergency UseHealth Organization Strategic Advisory GroupInterim Recommendation Supports UseBooster ShotTwo New IndicationsHelp PreventTreat Blood ClotsSeeks ApprovalFixed Duration RegimenUntreated Chronic Lymphocytic LeukaemiaSubmits Biologics License ApplicationRefractory Multiple
Janssen Submits Biologics License Application to U.S. FDA Seeking Approval of Teclistamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma - Vimarsana News

Janssen Submits Biologics License Application to U.S. FDA Seeking Approval of Teclistamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Published: December 29, 2021

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a Biologics License Application (BLA) to the U.S....

Source: prnewswire.com
Related Topics:
United StatesObrian KenneyPeter LebowitzJessica MooreMathai MammenAmerican Society Of Hematology Annual MeetingInternational Myeloma Working GroupCancer Research InstituteJanssen Pharmaceutical CompaniesJanssen Pharmaceutical Companies Of JohnsonJanssen Research DevelopmentAmerican Society Of HematologyAmerican Cancer SocietyNone Of The Janssen Pharmaceutical CompaniesDrug AdministrationEuropean CommissionAmerican Cancer Society Facts StatisticsExchange CommissionCompanies Of JohnsonEuropean Medicines AgencyBiologics License ApplicationGlobal Therapeutic Area HeadJanssen ResearchAmerican SocietyGlobal Head
New Data from MajesTEC-1 Study Show Continued Deep and Durable Responses of Teclistamab (BCMAxCD3 Bispecific Antibody) in Treatment of Heavily Pretreated Patients with Multiple Myeloma - Vimarsana News

New Data from MajesTEC-1 Study Show Continued Deep and Durable Responses of Teclistamab (BCMAxCD3 Bispecific Antibody) in Treatment of Heavily Pretreated Patients with Multiple Myeloma

Published: December 14, 2021

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced the first presentation of Phase 2 data and updated Phase 1 data from the...

Source: prnewswire.com
Related Topics:
United StatesYusri ElsayedObrian KenneyPhilippe MoreauJessica MooreJanssen Biotech IncAmerican Society Of Hematology Annual MeetingCancer Research InstituteJanssen Research DevelopmentJanssen Pharmaceutical CompaniesJanssen Pharmaceutical Companies Of JohnsonAmerican Society Of HematologyUniversity HospitalAmerican Cancer SocietyNone Of The Janssen Pharmaceutical CompaniesOther Administration ReactionsDrug AdministrationEuropean CommissionAmerican Cancer Society Facts StatisticsExchange CommissionCompanies Of JohnsonAmgen IncEuropean Medicines AgencyAmerican SocietyConfidence Interval